Visual, refractive outcomes positive at 9 months with Teneo excimer laser for myopia
Click Here to Manage Email Alerts
Key takeaways:
- Mean manifest refraction spherical equivalent improved from –5.67 ± 2.52 D before surgery to –0.04 ± 0.32 D after surgery.
- Patient satisfaction improved from 27.7% to 98.1%.
Patients with myopia and myopic astigmatism who underwent LASIK with the Bausch + Lomb Technolas Teneo 317 model 2 excimer laser experienced positive visual and refractive outcomes and a high level of satisfaction, according to a study.
“The data reveal a new generation of excimer laser technology that provides excellent and consistent outcomes without the need for a nomogram adjustment,” Anthony Wallace, vice president and general manager, U.S. Surgical, Bausch + Lomb, told Healio in an email. “The Teneo checks all the boxes by being the smallest and fastest laser on the market with ablation times of 1.2 seconds per diopter and precise refractive corrections through a plug-and-play dynamic.”
The prospective multicenter study, published in the Journal of Refractive Surgery by George O. Waring IV, MD and colleagues, included 333 eyes of 168 patients with a manifest refraction spherical equivalent between –1 D and –11.5 D with or without astigmatism and an uncorrected distance visual acuity of 20/40 or worse; 17 eyes discontinued the study, leaving 316 eyes at the 9-month analysis. There were no nomogram adjustments made. Participants completed the Patient-Reported Outcomes with LASIK questionnaire before and after surgery.
At 9 months, 97.8% of eyes achieved uncorrected distance visual acuity of 20/25 or better, and all eyes achieved corrected distance visual acuity of 20/25 or better. Mean manifest refraction spherical equivalent improved from –5.67 ± 2.52 D before surgery to –0.04 ± 0.32 D after surgery. Residual refractive error was within ±0.5 D in 92.7% of eyes and within ±1 D in 99.1% of eyes.
Compared with a 27.7% patient satisfaction rate before the surgery, “we’ve seen 98.1% patient satisfaction post-procedure, with 99% of patients reporting little to no difficulty driving at night,” Wallace said. “These features enable the Teneo to reenergize the stagnant refractive arena, which had its last excimer approval more than a decade ago.”
No study eyes lost two or more lines of corrected distance visual acuity, and residual refractive cylinder was within ±0.5 D in 93% of eyes and within ±1 D in 99.4% eyes.
“We are certainly not stopping here,” Wallace said. “We are working toward an expansion of indications to include hyperopia and transepithelial PRK in the U.S.”
Collapse
Read more about
Click Here to Manage Email Alerts